MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, through May 20, 2024.

迈阿密，2024年3月15日（环球通讯社）--Avenue Therapeutics，Inc.（纳斯达克：ATXI）（“Avenue”或“公司”），一家专注于开发和商业化治疗神经系统疾病的专业制药公司，今天宣布，根据2024年3月11日的决定，纳斯达克听证会小组批准了该公司的延期请求，以证明其符合所有适用的继续在纳斯达克资本市场上市的标准，包括1.00美元的投标价格和250万美元的股东权益要求，直至2024年5月20日。

The Company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on Nasdaq; however, there can be no assurance that the Company will be able to do so..

该公司正在考虑所有可用的选项，以使其能够及时证明符合继续上市标准，并保持其在纳斯达克的上市；但是，无法保证公司能够做到这一点。。

About Avenue Therapeutics

关于Avenue Therapeutics

Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol, which is in Phase 3 clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting.

Avenue Therapeutics，Inc.（纳斯达克：ATXI）是一家专业制药公司，专注于神经系统疾病治疗方法的开发和商业化。它目前正在开发三种资产，包括AJ201，一种用于脊柱和延髓性肌萎缩症的一流资产，BAER-101，一种用于中枢神经系统疾病的口服小分子选择性GABAAα2，α3受体阳性变构调节剂，以及IV曲马多，它正在进行第三阶段临床开发，用于在医学监督的医疗保健环境中管理成人急性术后疼痛。

Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com..

Avenue总部位于佛罗里达州迈阿密，由Fortress Biotech，Inc.（纳斯达克股票代码：FBIO）创立。有关更多信息，请访问www.avenuetx.com。。

Forward-Looking Statements

前瞻性声明

This press release contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this press release, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的预测性或“前瞻性声明”。本新闻稿中包含的除当前或历史事实声明以外的所有声明，包括表达我们的意图、计划、目标、信念、期望、策略、预测或与我们未来活动或其他未来事件或条件有关的任何其他声明，均为前瞻性声明。

The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects.

“预期”、“相信”、“继续”、“可能”、“估计”、“预期”、“打算”、“可能”、“计划”、“预测”、“项目”、“将会”、“应该”、“将会”等词语以及类似的表述旨在识别前瞻性陈述。这些报表基于管理层对我们的业务、行业和影响我们财务状况、经营成果或业务前景的其他条件的当前预期、估计和预测。

These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties.

这些声明并不能保证未来的业绩，涉及难以预测的风险、不确定性和假设。因此，由于存在众多风险和不确定性，实际结果和结果可能与前瞻性声明中表达或预测或暗示的结果存在重大差异。

Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: expectations for increases or decreases in expenses; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our researc.

可能导致这些结果和结果不同的因素包括但不限于以下风险和不确定性：对费用增加或减少的预期；对我们的候选药品或我们可能获得或许可的任何其他产品的临床和临床前开发，制造，监管批准和商业化的期望；我们使用临床研究中心和其他承包商；期望产生资本支出以扩大我们的研究。

Contact:

联系人：

Jaclyn Jaffe

Jaclyn Jaffe

Avenue Therapeutics, Inc.

Avenue Therapeutics公司。

(781) 652-4500

(781) 652-4500

ir@avenuetx.com

ir@avenuetx.com